Significant prognostic heterogeneity exists within the substages of melanoma; therefore, novel prognostic biomarkers are needed to provide information on the risk of recurrence. Limited available data suggest prognostic significance for circulating melanoma cells (CMCs); there is a need for a sensitive, reproducible, and standardized identification technique. Using a semiautomated technology, we sought to determine whether CMCs could be identified reliably in stage I-IV melanoma patients and whether the presence of CMC correlated with known prognostic factors. CMCs were detected in the peripheral blood (7.5 ml) of patients with stage I-IV melanoma (n = 89) using the CellSearch system. CD146 + cells were immunomagnetically enriched; nucleated HMW-MAA + /CD45 − /CD34 − cells were considered CMCs. One or more CMCs was detected in 45% of all patients, varying with stage of disease (stages I/II, III, and IV: 35, 44, and 86%, respectively; P = 0.03, for stage I/II vs. stage IV); 55% had one CMC, 32% had two CMCs, and 13% had three or more CMCs identified. The presence of CMCs in the blood was associated with histologic subtype, particularly in patients with stage I/II disease (superficial spreading 18% vs. acral lentiginous 75%). Using a semiautomated technique, CMCs can be identified in a significant number of melanoma patients. These data support further study with longer follow-up and longitudinal/serial time points to better determine the identification rates and prognostic significance of CMCs in stage I-IV melanoma patients. Melanoma Res 25:335-341
Introduction
The incidence of malignant cutaneous melanoma has increased significantly worldwide over the last 20 years, with an estimated 232 000 new cases in 2012 and over 55 000 deaths [1, 2] . Although the majority of patients are diagnosed with early stage disease, significant prognostic heterogeneity exists within each of the substages of melanoma [1] . Although the importance of prognostic variables such as ulceration and mitotic activity have become apparent, a significant number of patients diagnosed with melanoma develop recurrent disease [3, 4] . Therefore, novel prognostic markers are needed to better identify this subset of patients.
Circulating melanoma cells (CMCs) were first identified in the blood of melanoma patients 30 years ago, generating considerable interest in the clinical and biological significance of these cells [5] [6] [7] . Unfortunately, there is significant variability in the prognostic significance of CMCs in the limited number of published reports to date . The varied, nonstandardized methodologies utilized for the detection and quantification of rare CMCs likely contribute toward these disparate findings. A sensitive, reproducible, standardized CMC identification technique is needed to accurately assess the prognostic significance of CMCs [27] .
To date, the semiautomated CellSearch system is the only FDA-approved methodology for the identification and enumeration of circulating tumor cells (CTCs) in whole blood (metastatic prostate, breast, and colon cancers). Three landmark studies led to FDA approval of the CellSearch methodology. A study by de Bono et al. [28] showed that ≥ 5 CTCs/7.5 ml blood detected at baseline was an independent prognostic factor for overall survival in metastatic castration-resistant prostate cancer. This study also showed that CTC enumeration before and after treatment was a better predictor of overall survival than prostate-specific antigen values. Similar findings were reported in metastatic breast cancer, whereby ≥ 5 CTCs/7.5 ml blood at baseline (before starting a new systemic chemotherapy) and at each follow-up time point during therapy predicted both progression-free and overall survival [29] . In patients with metastatic colorectal cancer, ≥ 3 CTCs/7.5 ml blood at baseline and during follow-up predicted progression-free and overall survival [30] . Data are emerging on the predictive significance of CTCs in patients with nonmetastatic breast cancer. Results from the French REMAGUS trial [31] , the German SUCCESS trial, [32] , and our group [33] have shown that the identification of one or more CTC predicts progression-free and overall survival in patients with nonmetastatic breast cancer. However, the CellSearch system has not been widely utilized for CMC detection in patients with cutaneous melanoma. A handful of studies have been published indicating the prognostic significance of CMCs using the CellSearch in the metastatic setting, whereby patients with two or more CMCs/7.5 ml peripheral blood throughout treatment had shortened overall survival than those patients with less than two CMCs throughout treatment [19, 34, 35] .
In the present study, we investigated the identification of CMCs in the peripheral blood of patients with stage I-IV melanoma using the CellSearch system. We determined whether any associations exist between CMC identification and known prognostic variables, such as tumor size, lymph node status, Clark level, AJCC stage, histologic subtype, ulceration, and mitotic rate.
Methods

Patients
Patients with clinical stage IB-IV cutaneous melanoma and healthy control participants were enrolled from January 2012 to December 2012 in an institutional review board-approved protocol (University of Texas MD Anderson Cancer Center LAB 11-0314; Principal Investigator, A. Lucci) for the detection of minimal residual disease in peripheral venous blood. To increase the likelihood of CMC identification, patients with Breslow thickness less than 0.75 mm and no unfavorable features (mitotic figures, ulceration) were excluded. We obtained informed consent from all patients and agematched control participants before blood collection. Patient blood samples were drawn at the time of primary tumor diagnosis or at relapse; control participant blood samples were obtained immediately following informed consent. Individual patient and control participant results were blinded from investigators using a random number system as the unique patient identifier.
Staging and classification
Clinicopathologic data were obtained from the medical record. Data analyzed included tumor size, lymph node status, Clark level, AJCC stage [36] , ulceration, mitotic activity, and histologic subtype. We designated the primary TNM staging [primary tumor (T), regional nodes (N), distant metastasis (M)] in accordance with the criteria set by the American Joint Commission on Cancer, and is reported as pathologic stage after completion of surgical therapy, unless otherwise noted [36] . Pathologic review of the primary melanoma, including histologic subtype, Clark level, the presence of ulceration, and mitotic figures, was performed at UT MD Anderson for the entire patient cohort. Lymph node status was determined by the presence or absence of lymph node metastasis as reported at the time of operation, either by sentinel lymph node (SLN) biopsy or by lymphadenectomy as clinically appropriate.
Circulating melanoma cell analysis
Peripheral venous blood was collected in one (10 ml glass) tube containing CellSave preservative for the detection of CMCs by the CellSearch (Janssen, Raritan, New Jersey, USA) CMC assay. Following the manufacturer's protocol, the CellSearch CMC assay was performed within 96 h of blood collection at the University of Texas MD Anderson Cancer Center. The CellSearch test uses ferrofluids coated with CD146 antibodies to immunomagnetically enrich melanoma cells, which are further identified using fluorescently labeled antibodies to detect a combination of highmolecular-weight melanoma associated antigen (HMW-MAA; clone 9.2.27; Janssen, LLC, Raritan, New Jersey, USA), CD45, and CD34 [19] . CMCs were defined as CD146 + , HMW-MAA + , CD45 − , CD34 − , and nucleated (DAPI + ) cells as described previously [19] . CMC results were reviewed by a qualified laboratory technician who was blinded to any patient or control participant information. In addition, random samples were also reviewed independently by another qualified laboratory technician to validate CMC identification.
Statistical analysis
For categorical variables, descriptive statistics were compared using χ 2 or Fisher's exact test; Wilcoxon's rank sum test (t-test) and the Kruskal-Wallis test (analysis of variance) were used to compare the distributions of continuous variables among different groups. Kappa inter-rater analysis was used to determine tube-to-tube variability. Statistical analyses were carried out using SPSS version 19 statistical software (IBM Corp., Armonk, New York, USA).
Results
Clinicopathologic features
The clinicopathologic features of the patients are described in Table 1 . Eighty-nine patients were included in the study, median age 55 years. Fifty-two of 89 (58%) patients were men and 85/89 (96%) were white. Twentyone of 89 (26%) patients had pathologic stage I disease, 18/89 (21%) were stage II, 39/89 (46%) were stage III, and 7/89 (8%) had stage IV disease. Thirty-one of 61 (51%) patients had positive SLN, 30/61 (49%) were SLN negative, and the SLN status was unknown for 28 patients. The most common histologic type was superficial spreading (28/89 patients, 32%), with 18/89 (20%) classified as nodular and 7/89 (8%) as acral lentiginous; the rest were either other (13%), unknown primary (12%), or unclassified (15%). Fifteen of 70 (21%) patients had tumors with Clark level I/II, the majority of patients (52/70, 74%) had Clark level IV tumors, 4% of patients had Clark level V, and the Clark level was unavailable for 19 patients. Sixty-one of 67 (91%) patients had one or more mitotic figure, 6/67 (9%) had less than one mitotic figure, and the number of mitotic figures was unavailable for 22 patients. Ulceration was present in 35% of patients. One or more CMCs were identified in 21/89 (21%) of patients, two or more CMCs were identified in 12/89 (13%) of patients, and five patients (6%) had three or more CMCs.
Circulating melanoma cells Figure 1 shows a representative CMC from the peripheral blood from a patient with clinical stage II disease detected by the CellSearch assay. One or more CMCs were detected in 38 of 89 (43%) of patients within our patient cohort, although the number of CMCs varied significantly on the basis of stage of disease (Table 2) . One or more CMCs were identified in six of 21 (29%) of patients with stage I disease, seven of 18 (39%) with stage II, 17/39 (44%) with stage III, and six of seven patients (86%) with stage IV disease (Table 2 ; P = 0.019 stage I vs. stage IV). Two or more CMCs were identified in three of 21 (14%) stage I patients, three of 18 (17%) stage II patients, seven of 39 (18%) stage III, and two of seven (29%) stage IV patients. For the entire patient cohort, CMCs were equally prevalent in patients with the presence or absence of standard prognostic and predictive markers. CMCs were detected in 14 of 39 patients (36%) with pN0 disease and 18 of 39 patients (46%) with N + disease ( Table 2 ; P = 0.638). We observed no statistically significant differences between the occurrences of CMCs and macroscopic verses microscopic involvement in the lymph nodes. Primary tumor ulceration was not associated with the presence of CMCs as CMCs were identified in 17 of 45 patients (38%) with primary tumor ulceration and 10 of 24 patients (42%) without ulceration (Table 2 ; P = 0.753).
Circulating melanoma cells and lymph node positivity
CMCs were detected in 48% of patients with clinical stage I or II disease who underwent SLN biopsy, followed by lymphadenectomy for pN + disease compared with a 32% CMC positivity rate for clinical stage I or II patients with pN0 disease (Figure 2 ; P = 0.11).
Circulating melanoma cell detection in healthy control participants
We performed CMC assessment on 70 age-matched, healthy control participants. The overall positivity rate for healthy control participants was 2.9%; one control subject of 70 (1.4%) had one CMC and one control subject of 70 (1.4%) had two CMCs. We are continuing to enroll and monitor control participants to establish the positivity rates for healthy individuals. We will monitor healthy participants closely to determine whether they develop melanoma or other types of cancers. To date, none of the control participants have developed any carcinomas.
Tube-to-tube variability
We carried out duplicate CMC analyses on 31 samples. Because low numbers of CMCs were identified within our patient cohort, we included both patient samples as well as healthy control samples for our tube-to-tube variability analyses. The resultant κ inter-rater agreement was 0.88.
Discussion
The process of metastasis is a multistep process that begins with the invasion of malignant cells through the basement membrane, intravasation into the blood stream, followed by extravasation, implantation, and proliferation in distant sites [37] . The rate of tumor cell shedding into the blood stream is estimated to be ∼ 3 × 10 6 cells/g of tissue/24 h [38] .
The ability to detect circulating cells routinely in the blood of melanoma patients has recently become available [5] [6] [7] . A wide variety of methodologies, utilizing CMC size (isolation by size of epithelial tumor cells) [39] , mRNA (rtPCR) [5] [6] [7] [8] [9] [10] [12] [13] [14] [15] [16] [17] [18] [20] [21] [22] [23] [24] 26, [40] [41] [42] [43] [44] , and protein expression [19, 34, 35] , have been used for CMC detection, making the interpretation of available studies difficult. Nevertheless, several studies have shown that the detection of CMC may represent a biomarker that can identify metastatic disease spread [8,9,11,13,16-18, 21,24-26,40-42,45] . PCR-based techniques have been used to monitor CMCs for treatment response in metastatic melanoma patients receiving chemotherapy and biochemotherapy [12, 14, 15, 20, 22, 23] . However, the reproducibility of PCR-based detection methods is low [43, 44] , which hinders their reliability and implementation in routine clinical practice.
To our knowledge, this study is one of the first reports utilizing the semiautomated CellSearch system to detect CMCs in stage I-IV melanoma patients. As only limited reports have been published using CellSearch for the detection of CMCs in melanoma (all in the metastatic setting), we carried out a blinded study of CMC assessment in healthy control participants as well as tubeto-tube variability analysis to validate the sensitivity and reproducibility of the CellSearch methodology. Circulating melanoma cells are identifiable in all stages of melanoma. These pseudocolored images show a circulating melanoma cell from a patient with clinical stage II disease detected by the CellSearch system using a CMC kit. Cells with positive staining for the melanoma marker high-molecularweight melanoma-associated antibody (HMW-MAA, PE; green) and nuclear DAPI staining (pink) with no staining for CD45/CD34 were considered CMCs. CMC, circulating melanoma cell; DAPI, 4′,6-diamidino-2-phenylindole; PE, phycoerythrin. The CMC 2.9% detection rate that we observed for healthy control individuals is in agreement with the 6% reported by Rao et al. [19] (the only study to date that has reported CMC values for control participants using the CellSearch methodology). We also assessed tube-to-tube variability for 31 random patients/control individuals by comparing the CMC counts in duplicate tubes; our observed κ integer value was 0.88. Therefore, we used a single 7.5 ml CellSave tube for CMC assessment.
In the present study, CMCs were identified in 38 of 89 (43%) patients with melanoma. CMCs were detected in 86% of patients with stage IV disease compared with 29% of patients with stage I (P = 0.019) disease; however, CMC detection in stage II (39%, P = 0.063) and stage III (44%, P = 0.083) patients was not significantly different compared with stage IV patients. This is likely because of the limited number of patients included in this study. Previous studies have reported CMC identification rates of 8-70% in patients with stage I-III disease [8, 10, 18, 26] . This variability is likely related to the vast array of isolation, enrichment, and detection methodologies used previously to identify CMCs.
We did not observe any significant associations between CMC identification and histologic subtype. Although the study was not powered to carry out formal statistical analyses comparing CMC identification on the basis of histologic subtype, we noted that 31% of patients with superficial-spreading melanoma had CMCs identified in peripheral blood, whereas CMCs were identified in 71% of patients with acral lentiginous and 44% of patients with nodular melanoma histologic subtypes. Although histologic subtype has not been associated previously with differences in prognosis, the observed increased incidence of CMCs in patients with nonsuperficial spreading subtypes warrants further investigation. We did not find any association of other well-known prognostic factors, such as tumor thickness, Clark level, ulceration, or mitotic activity, with the presence of CMCs in the blood. However, the small number of patients with zero mitotic figures (9%) in our cohort limited the power of the statistical analysis that was carried out to evaluate this important prognostic marker with CMC detection.
Although AJCC stage remains the best predictor of the risk of recurrence in patients with melanoma, there is a large degree of heterogeneity even within stage groups with respect to outcome and/or disease progression [4, 36] . Currently available prognostic factors are inadequate at identifying the population of patients likely to develop recurrence and would thus benefit from adjuvant therapy. To determine whether any associations existed between the presence of CMC and lymph node positivity, we evaluated the identification of CMCs in patients who were diagnosed with clinical stage I or II disease who had negative SLN at surgery compared with those who had positive SLNs at surgery (pathologic stage III). Interestingly, 32% of SLN-negative patients had CMCs detected in the blood, compared with 48% of SLN-positive patients, which trended toward, but did not reach statistical significance ( Fig. 2 ; P = 0.11). It is possible that statistical significance was not achieved because of the small numbers of patients within these subgroups. It is also plausible to hypothesize that there are two distinct routes of dissemination, hematogenous and lymphatic, which can occur independently. This hypothesis is supported by published studies that did not identify a significant correlation between CTC detection and lymph node positivity in nonmetastatic breast cancer patients, [33, 46] and reports indicating that 10-15% of melanoma patients with lymph node negative disease develop recurrences [47] [48] [49] . These data suggest that CMC assessment might provide additional prognostic information to better identify patients at risk of regional metastasis and support further investigation into the utility of CMCs as an independent prognostic variable.
Our study is limited by the relatively small sample size. As the CMC detection rates have not been established for early-stage melanoma patients using the CellSearch methodology, for this initial proof-of-principle study, the patient cohort was skewed toward a higher-risk population. In addition, patients in this study were enrolled at various time points in their care (initial diagnosis, time of recurrence, etc.), making it difficult to apply these data to a broad patient population. However, these data indicate that CMCs can be identified consistently in all stages of melanoma with the CellSearch system. Furthermore, these data support prospective studies with longer follow-up and longitudinal/serial time points to establish CMC detection rates and to better assess the prognostic significance of CMCs in melanoma patients. To achieve these objectives, we are continuing to enroll patients and have modified our original protocol to include longer follow-up and longitudinal CMC analyses. In conclusion, using this semiautomated technique, CMCs were identified in a significant number of melanoma patients, and their presence correlates with advancing AJCC stage. In patients with early-stage melanoma, the presence of CMCs may also be related to histopathologic subtype, although the clinical significance of this finding is unknown at this time. These data highlight the need for further prospective evaluation of CMCs in patients with cutaneous melanoma.
